Glenmark Pharmaceuticals Intrinsic Value
Glenmark Pharmaceuticals intrinsic value. Glenmark Pharmaceuticals (GLENMARK) median intrinsic value is ₹4525.71 from 10 valuation models (range ₹783–₹6521), vs current price ₹2608.50 — +73.5% upside (Trading Below Calculated Value), margin of safety 42.4%. Browse GLENMARK financial statements for revenue, profit, balance sheet and cash flow data.
GLENMARK Valuation Methods Summary — DCF, Graham Number & P/E
Glenmark Pharmaceuticals intrinsic value across 10 models vs current price ₹2608.50 — upside/downside and value range per method. Analyse GLENMARK shareholder distribution to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹822.80 | ₹658.24 - ₹987.36 | -68.5% | EPS: ₹37.40, Sector P/E: 22x |
| Book Value Method | asset | ₹6521.25 | ₹5869.12 - ₹7173.38 | +150.0% | Book Value/Share: ₹3754.29, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹5217.00 | ₹4695.30 - ₹5738.70 | +100.0% | Revenue/Share: ₹5942.86, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹5217.00 | ₹4695.30 - ₹5738.70 | +100.0% | EBITDA: ₹1968.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹6521.25 | ₹5217.00 - ₹7825.50 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹782.55 | ₹704.29 - ₹860.81 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹782.55 | ₹704.29 - ₹860.81 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹4525.71 | ₹4073.14 - ₹4978.28 | +73.5% | ROE: 10.0%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹1777.42 | ₹1599.68 - ₹1955.16 | -31.9% | EPS: ₹37.40, BVPS: ₹3754.29 |
| Dividend Yield Method | dividend | ₹782.55 | ₹704.29 - ₹860.81 | -70.0% | DPS: ₹5.00, Target Yield: 2.5% |
GLENMARK Intrinsic Value vs Market Price — All Valuation Models
Glenmark Pharmaceuticals fair value range ₹783–₹6521 vs current market price ₹2608.50 across 10 valuation models. For current market price and key ratios, visit Glenmark Pharmaceuticals share price chart.
GLENMARK Intrinsic Value Analysis — Undervalued or Overvalued?
Glenmark Pharmaceuticals median intrinsic value ₹4525.71, current price ₹2608.50 — Trading Below Calculated Value by 73.5%, margin of safety 42.4%.
What is the intrinsic value of GLENMARK?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Glenmark Pharmaceuticals (GLENMARK) is ₹4525.71 (median value). With the current market price of ₹2608.50, this represents a +73.5% variance from our estimated fair value.
The valuation range spans from ₹782.55 to ₹6521.25, indicating ₹782.55 - ₹6521.25.
Is GLENMARK undervalued or overvalued?
Based on our multi-method analysis, Glenmark Pharmaceuticals (GLENMARK) appears to be trading below calculated value by approximately 73.5%.
GLENMARK Financial Health — Key Ratios vs Industry Benchmarks
Glenmark Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 10.0% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 12.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.84x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
GLENMARK Cash Flow Quality — Operating & Free Cash Flow
Glenmark Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹3,445 Cr | ₹2,827 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹-828 Cr | ₹-828 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-265 Cr | ₹-265 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹625 Cr | ₹368 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹1,109 Cr | ₹951 Cr | Positive Free Cash Flow | 8/10 |